C&L Therapeutics is a preclinical stage biotech company focused on developing innovative therapeutics for the treatment of cancers and neuromuscular diseases with a proprietary small molecule STAR platform library to modulate RNA biology. Our flagship pipeline CL101 (Immune Checkpoint Inhibitor (ICI) booster), which we have developed in strategic collaboration with Jubilant Biosys, is a multikinase inhibitor targeting specific spectrum of oncogenic Receptor Tyrosine Kinases (RTKs) and GSK-3 with a potential to augment the anti-tumor effects by enhancing T-cell responses through the transcriptional inhibition of PD-1 and LAG-3 when combined with immune checkpoint Inhibitors (ICPI) such as Keytruda and Opdivo. In particular, CL101 can effectively reverses the loss of skeletal muscle protein and recovers the muscle strength in animal studies, paving the way to develop next-generation cancer therapy to address the low-response rate of CPI and high prevalence of cachexia in cancer patients. We also develop a direct cell reprogramming agent to generate clinically relevant cell types from patient-derived differentiated somatic cells via "trans-differentiation". This approach can provide a powerful tool for regenerative, precision medicine.
